KRAS and neoplasm: By contrast, in low-immunogenic tumors, while KRAS G12C inhibitors improved antigen presentation and T-cell activation by remodeling the TME, these changes failed to significantly enhance tumor sensitivity to immune checkpoint blockade (146).